Case Report| Volume 61, P472.e9-472.e13, November 2019

A Novel Frameshift COL3A1 Variant in Vascular Ehlers-Danlos Syndrome

  • Sydney L. Olson
    Minneapolis Heart Institute, Minneapolis, MN
    Search for articles by this author
  • Mitzi L. Murray
    GeneDx, Inc., Gaithersburg, MD
    Search for articles by this author
  • Nedaa Skeik
    Correspondence to: Nedaa Skeik, MD, FACC, FACP, FSVM, RPVI, Associate Professor of Medicine Section Head, Vascular Medicine Medical Director, Thrombophilia & Anticoagulation Clinic Medical Director, Hyperbaric Medicine Medical Director, Vascular Laboratories Minneapolis Heart Institute®, Abbott Northwestern Hospital - part of Allina Health, 920 E. 28th Street, Suite 300, Minneapolis, MN 55407, USA
    Minneapolis Heart Institute, Minneapolis, MN
    Search for articles by this author
Published:August 05, 2019DOI:
      Ehlers-Danlos syndromes (EDSs) are a group of heritable connective tissue disorders with distinct genetic etiologies. Of the 13 currently recognized types of EDS, the vascular type EDS (vEDS) is generally considered the most severe and is associated with a decreased life expectancy due to spontaneous arterial, intestinal, and or uterine rupture. Diagnosis of vEDS is supported by genetic testing confirming the presence of pathogenic variations in COL3A1, a type III procollagen gene. Management of vEDS is usually conservative with control of hemodynamic stress, frequent cardiovascular imaging, and, if indicated, a thoughtful endovascular intervention or surgical repair. We present a novel frameshift variant in COL3A1 leading to vEDS with multiple vascular involvements. Based on our literature review, this variant has not been reported and may result in a less severe form of vEDS. Our case report provides insight into genetic variants and clinical expression of vEDS.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Annals of Vascular Surgery
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Malfait F.
        • Francomano C.
        • Byers P.
        • et al.
        The 2017 international classification of the Ehlers–Danlos syndromes.
        Am J Med Genet C Semin Med Genet. 2017; 175: 8-26
        • Pepin M.G.
        • Murray M.L.
        • Byers P.H.
        Vascular Ehlers-Danlos syndrome.
        in: Adam M.P. Ardinger H.H. Pagon R.A. GeneReviews®. University of Washington, Seattle, Seattle, WA1993
        Date accessed: August 6, 2018
        • Oderich G.S.
        • Panneton J.M.
        • Bower T.C.
        • et al.
        The spectrum, management and clinical outcome of Ehlers-Danlos syndrome type IV: a 30-year experience.
        J Vasc Surg. 2005; 42: 98-106
        • Pepin M.G.
        • Schwarze U.
        • Rice K.M.
        • et al.
        Survival is affected by mutation type and molecular mechanism in vascular Ehlers-Danlos syndrome (EDS type IV).
        Genet Med. 2014; 16: 881-888
        • Byers P.H.
        • Belmont J.
        • Black J.
        • et al.
        Diagnosis, natural history, and management in vascular Ehlers–Danlos syndrome.
        Am J Med Genet C Semin Med Genet. 2017; 175: 40-47
        • Pepin M.
        Clinical and genetic features of Ehlers–Danlos syndrome type IV, the vascular type.
        N Engl J Med. 2000; 342: 673-680
        • Abayazeed A.
        • Hayman E.
        • Moghadamfalahi M.
        • et al.
        Vascular type Ehlers-Danlos Syndrome with fatal spontaneous rupture of a right common iliac artery dissection: case report and review of literature.
        J Radiol Case Rep. 2014; 8: 63-69
        • Germain D.P.
        Ehlers-Danlos syndrome type IV.
        Orphanet J Rare Dis. 2007; 2: 32
        • Shalhub S.
        • Black J.H.
        • Cecchi A.C.
        • et al.
        Molecular diagnosis in vascular Ehlers-Danlos syndrome predicts pattern of arterial involvement and outcomes.
        J Vasc Surg. 2014; 60: 160-169
        • Eagleton M.J.
        Arterial complications of vascular Ehlers-Danlos syndrome.
        J Vasc Surg. 2016; 64: 1869-1880
        • Leistritz D.F.
        • Pepin M.G.
        • Schwarze U.
        • et al.
        COL3A1 haploinsufficiency results in a variety of Ehlers-Danlos syndrome type IV with delayed onset of complications and longer life expectancy.
        Genet Med. 2011; 13: 717-722
        • Beridze N.
        • Frishman W.H.
        Vascular Ehlers-Danlos syndrome: pathophysiology, diagnosis, and prevention and treatment of its complications.
        Cardiol Rev. 2012; 20: 4-7
        • Ong K.-T.
        • Perdu J.
        • De Backer J.
        • et al.
        Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.
        Lancet. 2010; 376: 1476-1484
        • Snow T.
        Segmental arterial mediolysis. Radiology Reference Article. Radiopaedia.